

PTO/SB/08A (08-03)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 12 of 149**Complete if Known**

Application Number	10/817,549
Filing Date	April 2, 2004
First Named Inventor	Ron Waksman et al.
Art Unit	3763
Examiner Name	
Attorney Docket Number	0341-0030.42

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
MFD		US- 2,750,517	06-12-1956	Baum	
		US- 2,965,761	12-20-1960	Horvath	
		US- 3,088,032	04-30-1963	Brunton	
		US- 4,471,765	09-18-1984	Strauss, et al.	
		US- 4,883,459	11-28-1989	Calderon	
		US- 5,472,403	12-05-1995	Comacchia, et al.	
		US- 5,554,119	09-10-1996	Harrison, et al.	
		US- 5,618,226	04-08-1997	Liprie	
		US- 5,683,345	11-04-1997	Waksman, et al.	
		US- 6,071,227	06-06-2000	Popowski, et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

Examiner Signature		Date Considered	12/12/04
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/817,549
		Filing Date	April 2, 2004
		First Named Inventor	Ron Waksman et al.
		Art Unit	3763
		Examiner Name	
Sheet <u>83</u>	of <u>147</u>	Attorney Docket Number	0341-0030.42

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MFD	1	NISAR SYED A.M., FEDER B., "Technique of After-Loading Interstitial Implants", Syed/Feder, Radiologia Clinica 46:458-476 (1977).	
	2	NISAR SYED et al., "Combination of External and Interstitial Irradiation in the Primary Management of Breast Carcinoma", CANCER vol. 46, No. 6, pp. 1360-1365 (1980).	
	3	PUTHAWALA et al., "Temporary Iridium 192 Implant in the Management of Carcinoma of the Prostate", ENDOCURIETHERAPY/HYPERTHERMIA ONCOLOGY 1:25-34 (1985).	
	4	NISAR SYED et al., "Transperineal Interstitial-Intracavitary "Syed-Neblett" Applicator in the Treatment of Carcinoma of the Uterine Cervix", ENDOCURIETHERAPY/HYPERTHERMIA ONC-	
		LOGY 2:1-13 (1985).	
	5	NISAR SYED A.M. et al., "Intraluminal Irradiation in the Treatment of Esophageal Cancer", ENDOCURIETHERAPY/HYPERTHERMIA ONCOLOGY 3:105-113 (1987).	
	6	FAXON et al., "Mechanism of Angioplasty and Its Relation to Restenosis", AMERICAN JOURNAL OF CARDIOLOGY 15:5B-9B (1987).	
	7	BOROK et al. "Rule of Ionizing Irradiation for 393 Keloids", I.J. RADIATION ONCOLOGY-BIOLOGY-PHYSICS 17:77-80 (1989).	
	8	KOVALIC/PEREZ, "Radiation Therapy Following Keloidectomy: A 20-Year Experience", I.J. RADIATION ONCOLOGY-BIOLOGY-PHYSICS 17:77-80 (1989).	
	9	MCCORMICK et al., "Breast Cancer", Chpt. 25 of INTERSTITIAL BRACHYTHERAPY 221-226 (1990).	

Examiner Signature		Date Considered	12/12/04
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/817,549
		Filing Date	April 2, 2004
		First Named Inventor	Ron Waksman et al.
		Art Unit	3763
		Examiner Name	
Sheet <u>84</u>	of <u>149</u>	Attorney Docket Number	0341-0030.42

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MFD	10	DAWSON, "Theoretic Considerations Regarding Low-Dose Radiation Therapy for Prevention of Restenosis after Angioplasty", THE READING HOSPITAL & MEDICAL CENTER 18(1) 4-7 (1991).	
	11	Skin, p. 261 of the American Medical Association Family Medical Guide, Editor Kunz.	
	12	Endovascular Low-Dose Irradiation Inhibits Neointima Formation after Coronary Artery Balloon Injury in Swine - A Possible Role for Radiation Therapy in Restenosis Prevention,	
		by Ron WAKSMAN, MD; Keith A. ROBINSON, PhD; Ian R. CROCKER, MD; Michael B. GRAVANIS, MD; Gustavo D. CIPOLLA, DVM; Spencer B. KING III, MD, CIRCULATION vol. 91, No. 5, pp. 1533	
		-1539 (Mar. 1, 1995). Submitted for publication Oct. 3, 1994.	
	13	Endovascular Low-Dose Irradiation Inhibits Neointima Formation after Coronary Artery Balloon Injury in Swine - A Possible Role for Radiation Therapy in Restenosis Prevention,	
		by Ron WAKSMAN, MD; Keith A. ROBINSON, PhD; Ian R. CROCKER, MD; Gustavo D. CIPOLLA, DVM; Spencer B. KING III, MD. Submitted for publication Mar. 25, 1994.	
	14	SCHWARTZ et al., "Effect of External Beam Irradiation on Neointimal Hyperplasia after Experimental Coronary Artery Injury", American College of Cardiology, JACC vol. 19,	
		No. 5, (Apr. 1992), pp. 1106-1113.	
	15	STEIDLE, B., "Preventative Percutaneous Radiation Therapy to Avoid Hyperplasia of the Intima after Angioplasty Combined with Stent Implantation", STRAHLENTHER ONKOL, (1994),	

Examiner Signature		Date Considered	12/12/04
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/817,549
		Filing Date	April 2, 2004
		First Named Inventor	Ron Waksman et al.
		Art Unit	3763
		Examiner Name	
Sheet <u>105</u>	of <u>149</u>	Attorney Docket Number	0341-0030.42

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
M P J		170:151-154.	
	16	WIEDERMANN et al., "Effects of High-Dose Intracoronary Irradiation on Vasomotor Function and Smooth Muscle Histopathology", AMERICAN PHYSIOLOGICAL SOCIETY, (1994), pp. H125-	
		H132.	
	17	ABBAS et al., "External Beam Irradiation Inhibits Neointimal Hyperplasia Following Balloon Angioplasty", INTERNATIONAL JOURNAL OF CARDIOLOGY, 44 (1994), 191-202.	
	18	LIERMANN et al., "Interventional Treatment and Clinics in Combination with Prophylactic Endovascular Radiation in the Therapy of Intimal Hyperplasia", RADIOLOGE, (1994) 34,	
		524-533.	
	19	SHIMOTAKAHAR and MAYBERG, "Gamma Irradiation Inhibits Neointimal Hyperplasia in Rats after Arterial Injury", STROKE, vol. 25, No. 2, pp. 424-428, (Feb. 1994).	
	20	WIEDERMANN et al., "Intracoronary Irradiation Markedly Reduces Restenosis after Balloon Angioplasty in a Porcine Model", American College of Cardiology, JACC, vol. 23, No. 6,	
		pp. 1491-1498 (May 1994).	
	21	FISCHELL et al., "Low-Dose, Beta-Particle Emission from 'Stent' Wire Results in Complete, Localized Inhibition of Smooth Muscle Cell Proliferation", BASIC SCIENCE REPORTS,	

Examiner Signature	<i>M. P. J.</i>	Date Considered	12/12/04
--------------------	-----------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/817,549
		Filing Date	April 2, 2004
		First Named Inventor	Ron Waksman et al.
		Art Unit	3763
		Examiner Name	
Sheet <u>116</u>	of <u>149</u>	Attorney Docket Number 0341-0030.42	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MF D		Circulation, vol. 90, No. 6, (Dec. 1994), pp. 2956-2963.	
	22	FRIEDMAN, "Pathogenesis of the Spontaneous Atherosclerotic Plaque", ARCHIVES OF PATHOLOGY, vol. 76, (Sept. 1963), 94-105.	
	23	FRIEDMAN et al., "Cortisone and Experimental Atherosclerosis", ARCHIVES OF PATHOLOGY, vol. 77, (Feb. 1964), 56-72.	
	24	FRIEDMAN et al., "Aortic Atherosclerosis Intensification in Rabbits by Prior Endothelial Denudation", ARCHIVES OF PATHOLOGY, vol. 79, (Apr. 1965), 345-356.	
	25	FRIEDMAN and BYERS, "Effect of Iridium 192 Radiation on Thromboatherosclerotic Plaque in the Rabbit Aorta", ARCHIVES OF PATHOLOGY, vol. 80, (Sep. 1965).	
	26	FRIEDMAN, FELTON, and BYERS, "The Antiatherogenic Effect of Iridium 192 upon the Cholesterol-fed Rabbit", Journal OF CLINICAL INVESTIGATION, vol. 43, No. 2, (1964), 185-192.	
	27	HILARIS, B.S., et al., ATLAS OF BRACHYTHERAPY Chapter 2, "Brachytherapy Instruments", title & cover pages, p. 28, pp. 42-43, (1988).	
	28	MELKERT, R., et al., "Luminal Narrowing after Percutaneous Transluminal Coronary Angioplasty. A Multivariate Analysis of Clinical, Procedural and Lesion Related Factors Affecting Long-term Angiographic Outcome in the PARK Study", J. INVASIVE CARDIOLOGY, vol. 6, No. 5, pp. 160-171 (Jun. 1994).	
	29	FISHMAN, D., et al., Abstract: "A Randomized Comparison of Coronary-stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease", NEW ENGLAND J. OF	

Examiner Signature <u>Matt [Signature]</u>	Date Considered <u>12/12/04</u>
--	---------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/817,549
		Filing Date	April 2, 2004
		First Named Inventor	Ron Waksman et al.
		Art Unit	3763
		Examiner Name	
Sheet <u>127</u>	of <u>149</u>	Attorney Docket Number	0341-0030.42

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MFD		MEDICINE, p. 496 (Aug. 25, 1994).	
	30	NICOLINI, F., et al., "Biology of Restenosis and Therapeutic Approach", ENDOVASCULAR SURGERY, vol. 72, No. 4, pp. 919-935 (Aug. 1992).	
	31	WEIDERMANN, J., et al., Abstract: "Intracoronary Irradiation Acutely Impairs Endothelial and Smooth Muscle Function as Assessed by Intravascular Ultrasound", Supplement to	
		CIRCULATION, vol. 86, No. 4, p. I-188, Abstract No. 0750 (Oct. 1992).	
	32	LANDAU, C., et al., "Percutaneous Transluminal Coronary Angioplasty", NEW ENGLAND J. OF MED., vol. 3330, No. 14, pp. 981-983 (Apr. 7, 1994).	
	33	PARANANDI, S., et al., "Contemporary Clinical Trials of Restenosis", J. OF INVASIVE CARDIOLOGY, vol. 6, No. 4, pp. 109-123 (May 1994).	
	34	WIEDERMANN et al., "Intracoronary Irradiation Markedly Reduces Restenosis after Balloon Angioplasty in a Porcine Model", JACC, vol. 23, No. 6, pp. 1491-1498 (May 1994).	
	35	GLAGOV, S., "Intimal Hyperplasia, Vascular Modeling, and the Restenosis Problem", CIRCULATION, vol. 89, No. 6, pp. 2888-2891 (Jun. 1994).	
	36	BOTTCHER et al., "Endovascular Irradiation - A New Method to Avoid Recurrent Stenosis after Stent Implantation in Peripheral Arteries: Technique and Preliminary Results", I.J.	
		RADIATION ONCOLOGY, BIOLOGY, PHYSICS, vol. 29, (Nov. 1994), 183-186.	

Examiner Signature		Date Considered	12/12/04
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/817,549
		Filing Date	April 2, 2004
		First Named Inventor	Ron Waksman et al.
		Art Unit	3763
		Examiner Name	
Sheet <u>188</u>	of <u>149</u>	Attorney Docket Number 0341-0030.42	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MFD	37	LIERMANN et al. "Prophylactic Endovascular Radiotherapy to Prevent Intimal Hyperplasia after Stent Implantation in Femoropopliteal Arteries", CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, (1994), 17:12-16.	
	38	Supplementary European Search Report - EP 97 92 2288.	
	39	Annex to the European Search Report on European Patent Application No. EP 97 92 2288.	
	40	HERRMAN, J., et al., "Pharmacological Approaches to the Prevention of Restenosis Following Angioplasty", DRUGS, 46(1): pp. 18-52 (1993).	
	41	LANGE, R., et al., "Southwestern Internal Medicine Conference: Restenosis: The Achilles Heel of Coronary Angioplasty", AMER. J. OF THE MEDICAL SCIENCES, vol. 306, pp. 265-273 (Oct. 1993)	
	42	MYLER, R., et al., "Restenosis after Coronary Angioplasty: Pathophysiology and Therapeutic Implications (Part 1 of Two Parts), J. OF INVASIVE CARDIOLOGY, vol. 5, No. 8, pp. 278-285, (Oct. 1993).	
	43	WEIDERMAN, J., et al., Abstract: "Intracoronary Irradiation Markedly Reduces Restenosis after Balloon Angioplasty in a Porcine Model", Supplement of CIRCULATION, vol. 88,	

Examiner Signature 	Date Considered <u>12/12/04</u>
--	---------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/817,549
		Filing Date	April 2, 2004
		First Named Inventor	Ron Waksman et al.
		Art Unit	3763
		Examiner Name	
Sheet 149	of 149	Attorney Docket Number 0341-0030.42	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MPO		No. 4, pt. 2, p. I-655, Abstract No. 3529 (Oct. 1993).	
L	44	Office Action for Serial Number 10/411,749 dated March 29, 2004.	

Examiner Signature		Date Considered	12/12/04
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

4/2/04

LIST OF PUBLICATIONS CITED BY APPLICANT			<u>Attv. Docket No.</u> 0341-0030.42		<u>Serial No.</u> Not Assigned	
			<u>Applicant</u> Ron WAKSMAN et al			
			<u>Filing Date</u> Herewith		<u>Group</u>	
U.S. PATENT DOCUMENTS						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
MFD	4,733,653	03/29/88	Leung et al	128	1.2	11/25/85
	4,955,895	09/11/90	Sugiyama et al	606	194	06/22/89
	5,084,001	01/28/92	van't Hooft et al	600	3	08/09/90
	5,267,954	12/07/93	Nita	604	22	05/05/92
	5,334,154	08/02/94	Samson et al	604	102	08/04/92
	5,413,557	05/09/95	Solar	604	96	08/24/93
	5,501,227	03/26/96	Yock	128	662.06	09/17/93
	5,540,236	07/30/96	Ginn	128	772	08/05/94
	5,540,659	07/30/96	Teirstein	604	104	08/30/94
	5,545,137	08/13/96	Rudie et al	604	96	03/30/95
	5,624,392	04/29/97	Saab	604	43	08/08/94
	5,843,028	12/01/98	Weaver et al	604	54	08/30/96
	FOREIGN PATENT DOCUMENTS					
	DOCUMENT NUMBER	DATE	APPLICANT	English Abstract	English Trans.	FILING DATE
MFD	DE 1 095 963	12/29/60	Wachsmann		X	07/15/59
OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS (Including Author, Title, Date, Pertinent Pages)						
EXAMINER: <i>[Signature]</i>				DATE CONSIDERED: 12/12/04		
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP form. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.						